Drug Type Antibody drug conjugate (ADC) |
Synonyms MRG 002, MRG002 |
Target |
Action antagonists, inhibitors |
Mechanism HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists), Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC11H22N4O4 |
InChIKeyAGGWFDNPHKLBBV-YUMQZZPRSA-N |
CAS Registry159858-33-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
HER2 Positive Transitional Cell Carcinoma | Phase 3 | China | 21 Mar 2023 | |
Advanced breast cancer | Phase 3 | China | 30 Jun 2021 | |
HER2 Positive Breast Cancer | Phase 3 | China | 30 Jun 2021 | |
Metastatic human epidermal growth factor 2 positive carcinoma of breast | Phase 3 | China | 30 Jun 2021 | |
metastatic non-small cell lung cancer | Phase 2 | China | 09 Oct 2022 | |
Resectable Lung Non-Small Cell Carcinoma | Phase 2 | China | 09 Oct 2022 | |
Advanced HER2-Positive Breast Carcinoma | Phase 2 | China | 23 Mar 2022 | |
Breast Carcinoma Metastatic in the Liver | Phase 2 | China | 23 Mar 2022 | |
Liver metastases | Phase 2 | China | 04 Mar 2022 | |
Metastatic HER2 positive gastroesophageal junction cancer | Phase 2 | China | 19 Jan 2022 |
NCT05263869 (SABCS2024) Manual | Phase 2 | HER2 Positive Breast Cancer HER2 Positive | 102 | MRG002 2.6 mg/kg | zqyprdjvau(piwsdoxwxo) = errlhqjnkr fwcbzfpgsx (fbspqmfcfx, 50.6 - 70.3) View more | Positive | 26 Nov 2024 |
MRG002 2.6 mg/kg (HER2 IHC 3+) | zqyprdjvau(zcxdcpolmh) = ffbsogchhh tfswfuruaw (mgimyjcklt ) View more | ||||||
NCT05338957 (ESMO2024) Manual | Phase 1/2 | Transitional Cell Carcinoma HER2-expressing | 33 | eulsnyulvl(osccuscmdf) = qxrxkbxzhk pudksaktfd (skxrhginlk ) View more | Positive | 15 Sep 2024 | |
Phase 2 | 43 | tjrqkjxyfx(sgquwodaib) = 31.8% zgbxlvotdp (ccoaadcxbf ) View more | Positive | 21 Sep 2022 | |||
Phase 2 | HER2 Positive Transitional Cell Carcinoma HER2 Positive | 58 | mdunspbsvb(muaeaswepo) = flvmdyhnim ixunwoaqry (anojvqyhbs ) View more | Positive | 25 Aug 2022 | ||
(Platinum-containing chemotherapy and PD-(L)1 treatment failed) | mdunspbsvb(muaeaswepo) = fyuohlpzke ixunwoaqry (anojvqyhbs ) View more | ||||||
NCT04742153 (ASCO2022) Manual | Phase 2 | HER2-Low Breast Carcinoma HER2 Lowexpression | 56 | rgpholedja(iqforiqpgl) = uaypelwbgl acoitjdpce (rftceniyfz ) View more | Positive | 02 Jun 2022 | |
(patients with visceral metastasis) | rgpholedja(iqforiqpgl) = zuqijqbfrp acoitjdpce (rftceniyfz ) View more | ||||||
Phase 2 | Unresectable Urothelial Carcinoma HER2 Positive | 39 | iqtvrxyyrb(wlssbvnxci) = bubgzzbsvt whcpzfoqkg (gqubucixau, 44.9 - 81.2) View more | Positive | 02 Jun 2022 | ||
(≥ 2 lines of treatment) | iqtvrxyyrb(wlssbvnxci) = lhvelaxlzl whcpzfoqkg (gqubucixau ) |